Application of atrasentan or pharmaceutically acceptable salt thereof in preparation of product for treating amyotrophic lateral sclerosis

• Main Authors: WANG XIAONA, GE MEIYI, LI YALONG, OU TIANMIAO
• Format: Patent
• Language: Chinese; English
• Published: 21.04.2023
• Subjects: FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The invention relates to the field of biological medicine, in particular to application of atrasentan or pharmaceutically acceptable salt thereof in preparation of a product for treating amyotrophic lateral sclerosis. The test result of the invention proves that the atrasentan can inhibit the formation of Vimentin-Beclin1-14-3-3 ternary complex, reduce the abnormal modification of TDP-43 protein and influence the expression level of autophagy markers LC3 protein and P62 protein. In addition, drosophila melanogaster tests show that the atrasentan can improve the movement ability of the drosophila melanogaster overexpressed by the TDP-43 protein, reduce generation of black spots in eyes of the drosophila melanogaster and prolong the life of the drosophila melanogaster in a high-temperature environment and a normal environment. The atrasentan can be used as a drug for treating amyotrophic lateral sclerosis, which has a development prospect. 本发明涉及生物医药领域，尤其涉及阿曲生坦或其药学上可接收的盐在制备治疗肌肉萎缩侧索硬化症产品中的应用。本发明的试验结果证明了阿曲生坦可抑制Vim